An integrated approach to the preservation of reproductive material in patients with oncological pathology
- Authors: Lapina I.A.1,2, Dobrokhotova Y.E.1, Malakhova A.A.1,2, Sorokin Y.A.2, Chirvon T.G.1, Gomzikova V.M.1,2, Taranov V.V.1,2, Olkhovskaya M.A.1
-
Affiliations:
- Pirogov Russian National Research Medical University
- Medsi group JSC
- Issue: Vol 26, No 7 (2024): Women's and men's health
- Pages: 420-426
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/270507
- DOI: https://doi.org/10.26442/20751753.2024.7.202838
- ID: 270507
Cite item
Full Text
Abstract
Background. Every year, the number of patients who face cancer without having time to realize their reproductive function increases. In view of this, there is a growing need to develop and improve various ways to preserve fertility in this category of patients. The most common techniques are in vitro maturation of oocytes and controlled ovarian stimulation followed by vitrification of oocytes and embryos. At the same time, transvaginal puncture (TVP) has a risk of developing complications such as bleeding or an infectious process. Disorders of the vaginal microflora also increase the likelihood of inflammatory diseases. In this regard, the correction of vaginal dysbiosis is an integral part of the protocols of assisted reproductive technologies before the TVP.
Aim. Development of an integrated approach to the preservation of reproductive material in patients with oncological pathology.
Materials and methods. A prospective randomized study of 39 women with an identified oncological process and bacterial vaginosis was conducted. The patients were divided into 2 groups: oral probiotic was added to clindamycin therapy in group 1, and vaginal probiotic in group 2. The ovarian reserve was examined for everyone, the qualitative composition of the vaginal microflora was determined, pH-metry was performed and related specialists were consulted if necessary.
Results. The patients are comparable in age and ovarian reserve. When using an oral probiotic, an improvement in the qualitative composition of the microflora was noted due to a decrease in opportunistic flora (Gardnerella vaginalis) and an increase in the number of lactobacilli. The vaginal probiotic showed comparable results, but the recurrence rate was 28%, while in group 1 it was 18%. It was noted that when taking Enterolactis Duo, the symptoms associated with chemotherapy treatment decrease. During the study, 396 oocytes were obtained, of which 212 are suitable for vitrification and fertilization.
Conclusion. Currently, the development of oncofertility methods and their improvement remain one of the urgent problems. Taking an oral probiotic helps to normalize the vaginal microflora, neutralize the risks of infectious complications in TVP, reduce the likelihood of recurrence of dysbiosis and the development of adverse events associated with chemotherapy. The use of ovulation stimulation demonstrates higher rates compared to in vitro maturation. However, a combination of these procedures can be used to increase the amount of material obtained, which is subsequently used in assisted reproductive technology protocols.
Full Text
##article.viewOnOriginalSite##About the authors
Irina A. Lapina
Pirogov Russian National Research Medical University; Medsi group JSC
Author for correspondence.
Email: doclapina@mail.ru
ORCID iD: 0000-0002-2875-6307
D. Sci. (Med.)
Russian Federation, Moscow; MoscowYulia E. Dobrokhotova
Pirogov Russian National Research Medical University
Email: Pr.Dobrohotova@mail.ru
ORCID iD: 0000-0002-7830-2290
D. Sci. (Med.), Prof.
Russian Federation, MoscowAnastasiya A. Malakhova
Pirogov Russian National Research Medical University; Medsi group JSC
Email: anastasimed@yandex.ru
ORCID iD: 0000-0002-2140-8000
Graduate Student
Russian Federation, Moscow; MoscowYury A. Sorokin
Medsi group JSC
Email: doclapina@mail.ru
ORCID iD: 0000-0001-9305-323X
Department Head
Russian Federation, MoscowTatiana G. Chirvon
Pirogov Russian National Research Medical University
Email: tkoltinova@gmail.com
ORCID iD: 0000-0002-8302-7510
Graduate Student
Russian Federation, MoscowValeriia M. Gomzikova
Pirogov Russian National Research Medical University; Medsi group JSC
Email: gomzval1402@gmail.com
ORCID iD: 0000-0001-6297-8811
Graduate Student
Russian Federation, Moscow; MoscowVladislav V. Taranov
Pirogov Russian National Research Medical University; Medsi group JSC
Email: vlastaranov@mail.ru
ORCID iD: 0000-0003-2338-2884
Graduate Student
Russian Federation, Moscow; MoscowMariya A. Olkhovskaya
Pirogov Russian National Research Medical University
Email: mashulchka@mail.ru
ORCID iD: 0009-0005-0754-710X
Resident
Russian Federation, MoscowReferences
- Lambertini M, Del Mastro L, Pescio MC, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1. doi: 10.1186/s12916-015-0545-7
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660
- ESHRE Guideline Group on Female Fertility Preservation; Anderson RA, Amant F, Braat D, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020;2020(4):hoaa052. doi: 10.1093/hropen/hoaa052
- Dolmans MM, Manavella DD. Recent advances in fertility preservation. J Obstet Gynaecol Res. 2019;45(2):266-79. doi: 10.1111/jog.13818
- Meirow D, Dor J, Kaufman B, et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod. 2007;22(6):1626-33. doi: 10.1093/humrep/dem027
- Practice Committees of the American Society for Reproductive Medicine, Society for Reproductive Biologists and Technologists, and Society for Assisted Reproductive Technology. Cryostorage of reproductive tissues in the in vitro fertilization laboratory: a committee opinion. Fertil Steril. 2020;114(3):486-91. doi: 10.1016/j.fertnstert.2020.06.019
- Савичева А.М., Будиловская О.В., Тапильская Н.И. Роль пероральных пробиотических лактобацилл в поддержании гомеостаза вагинального микробиома. Акушерство и гинекология: новости, мнения, обучение. 2023;11(1):33-42 [Savicheva AM, Budilovskaya OV, Tapilskaya NI. Role of oral probiotic lactobacilli in maintaining vaginal microbiome homeostasis. Obstetrics and Gynecology: News, Opinions, Training. 2023;11(1):33-42 (in Russian)]. doi: 10.33029/2303-9698-2023-11-1-33-42
- Ших Е.В. Клинико-фармакологические аспекты применения пероральных препаратов лактобактерий в лечении вагинальных дисбиозов. Акушерство и гинекология: новости, мнения, обучение. 2021;9(2):82-91 [Shikh EV. Pharmacological and clinical aspects of oral preparations of lactobacilli usage in treatment of vaginal dysbiosis. Obstetrics and Gynecology: News, Opinions, Training. 2021;9(2):82-91 (in Russian)]. doi: 10.33029/2303-9698-2021-9-2-82-91
- Larsson PG, Bergström M, Forsum U, et al. Bacterial vaginosis. Transmission, role in genital tract infection and pregnancy outcome: an enigma. APMIS. 2005;113(4):233-45. doi: 10.1111/j.1600-0463.2005.apm_01.x
- Радзинский В.Е., Соловьева А.В., Кузнецова О.А., Смирнова Т.В. Пероральные пробиотики: механизм двойного действия в коррекции дисбиозов. Что известно? Акушерство и гинекология: новости, мнения, обучение. 2023;11(Спецвыпуск):85-90 [Radzinsky VE, Solovieva AV, Kuznetsova OA, Smirnova TV. Oral probiotics: a dual action mechanism in correction of dysbiosis. What is known? Obstetrics and Gynecology: News, Opinions, Training. 2023;11(Suppl.):85-90 (in Russian)]. doi: 10.33029/2303-9698-2023-11-suppl-85-90
- Hall AB, Tolonen AC, Xavier RJ. Human genetic variation and the gut microbiome in disease. Nat Rev Genet. 2017;18(11):690-9. doi: 10.1038/nrg.2017.63
- Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect. 2007;13(7):657-64. doi: 10.1111/j.1469-0691.2007.01688.x
- Koirala R, Gargari G, Arioli S, et al. Effect of oral consumption of capsules containing Lactobacillus paracasei LPC-S01 on the vaginal microbiota of healthy adult women: a randomized, placebo-controlled, double-blind crossover study. FEMS Microbiol Ecol. 2020;96(6):fiaa084. doi: 10.1093/femsec/fiaa084
- Lu D, Yan J, Liu F, et al. Probiotics in preventing and treating chemotherapy-induced diarrhea: a meta-analysis. Asia Pac J Clin Nutr. 2019;28(4):701-10. doi: 10.6133/apjcn.201912_28(4).0005
- Мансурова А.С., Войцицкий В.Е., Красильников С.Э., и др. Роль пробиотиков в коррекции нежелательных явлений на фоне химиотерапии у пациенток со злокачественными новообразованиями яичников. Journal of Siberian Medical Sciences. 2022;6(4):15-24 [Mansurova AS, Voitsitsky VE, Krasilnikov SE, et al. The role of probiotics in the correction of adverse events during chemotherapy in patients with ovarian malignancies. Journal of Siberian Medical Sciences. 2022;6(4):15-24 (in Russian)]. doi: 10.31549/2542-1174-2022-6-4-15-24
- El Hachem H, Sonigo C, Benard J, et al. Comparison of GnRH agonist and hCG for priming in vitro maturation cycles in cancer patients undergoing urgent fertility preservation. PLoS One. 2018;13(12):e0208576. doi: 10.1371/journal.pone.0208576
- Marklund A, Eloranta S, Wikander I, et al. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer – a prospective nationwide Swedish multicenter study. Hum Reprod. 2020;35(4):929-38. doi: 10.1093/humrep/deaa029
- Delattre S, Segers I, Van Moer E, et al. Combining fertility preservation procedures to spread the eggs across different baskets: a feasibility study. Hum Reprod. 2020;35(11):2524-36. doi: 10.1093/humrep/deaa193
- Wang X, Gook DA, Walters KA, et al. Improving fertility preservation for girls and women by coupling oocyte in vitro maturation with existing strategies. Womens Health (Lond). 2016;12(3):275-8. doi: 10.2217/whe-2016-0019
Supplementary files
